Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran
Research article published in Scientific reports (2025)
Abstract
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than previously assumed. Idarucizumab, a monoclonal antibody fragment, binds to both free and thrombin-bound dabigatran, neutralizing its anticoagulant effects. However, its efficacy in reversing anticoagulation induced by dabigatran acylglucuronide remains unclear. This study aimed to evaluate whether idarucizumab differentially reverses the anticoagulant effects of dabigatran and dabigatran acylglucuronide. In vitro experiments were conducted using blood from healthy, drug-free donors. Plasma samples were spiked with either dabigatran or dabigatran acylglucuronide, followed by idarucizumab. Standard coagulation assays, including prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), as well as thrombin generation assays (TGA), were performed. At a concentration of 1 µM, idarucizumab demonstrated significantly greater reversal of dabigatran acylglucuronide-induced anticoagulation than that of dabigatran in PT, aPTT, and TT assays. Consistently, TGA showed stronger neutralization of dabigatran acylglucuronide, with IC50 values for Cmax, endogenous thrombin potential, and lag time at least 2.0-fold higher than those of dabigatran. These findings indicate that idarucizumab exerts a more potent reversal effect on dabigatran acylglucuronide compared to dabigatran.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than previously assumed.
Por qué esto importa para la hirudoterapia
Este estudio in vitro evaluó si idarucizumab revierte de forma diferencial los efectos anticoagulantes de dabigatrán frente a dabigatrán acilglucurónido (un metabolito activo), enriqueciendo plasma de donantes sanos con cada compuesto y añadiendo posteriormente idarucizumab. Halló que idarucizumab mostró una reversión significativamente mayor de la anticoagulación inducida por dabigatrán acilglucurónido que por dabigatrán en los ensayos de TP, TPTa, tiempo de trombina y generación de trombina, con valores de CI50 para la reversión del acilglucurónido al menos 2,0 veces superiores a los de dabigatrán. El resumen no menciona sanguijuelas, hirudoterapia, hirudina ni ningún compuesto derivado de sanguijuela. Se trata de un estudio puramente in vitro que utiliza muestras de plasma enriquecidas, sin datos clínicos ni en animales, y carece de relevancia defendible para la hirudoterapia o el secretoma de la sanguijuela.
Citación
Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran
Kim JM et al. · Scientific reports, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026